Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]- carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2323-2330

  Cusack Jr , James C ^a,b   Liu, Rong ^b   Baldwin Jr , Albert S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; GAMMA IRRADIATION; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL NUCLEUS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; I-KAPPA B PROTEINS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; NF-KAPPA B; TIME FACTORS; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0034192390     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ghosh, S., May, M. J., and Kopp. E. B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 16: 225-260, 1998.
2. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (Washington DC), 281: 1680-1683, 1998.
3. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med., 5: 412-417, 1999.
4. Wang, C-Y., Mayo, M., and Baldwin, A. S., Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
5. Bentires-Alj, M., Hellin, A. C., Ameyar, M., Chouaib, S., Merville, M. P., and Bours, V. Stable inhibition of nuclear factor κB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res., 59: 811-815, 1999.
6. Cunningham, D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur. J. Cancer, 32A: S1-S8, 1996.
7. Schmitt, C. A., and Lowe, S. W. Apoptosis and therapy. J. Pathol., 187: 127-137, 1999.
8. Wu, G. S., and El-Deiry, W. S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin. Cancer Res., 2: 623-633, 1996.
9. Kastan, M. B. Molecular determinants of sensitivity to antitumor agents. Biochim. Biophys. Acta, 1424: R37-R42, 1999.
10. el-Deiry, W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol., 9: 79-87, 1997.
11. Baldini, N. Multidrug resistance-a multiplex phenomenon. Nat. Med., 3: 378-380, 1997.
12. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
13. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
14. Fulda, S., Susin, S. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998.
15. Kirsch, D. G., and Kastan, M. B. Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol., 16: 3158-3168, 1998.
16. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., and Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
17. Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., and Fukuoka, M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol., 16: 1068-1074, 1998.
18. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K., and Kishimoto, S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol., 10: 1775-1780, 1992.
19. de Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J. M., Gouyette, A., Madelaine, I., Marty, M. E., and Mathieu-Boue, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res., 54: 4347-4354, 1994.
20. Oshita, F., Noda, K., Nishiwaki, Y., Fujita, A., Kurita, Y., Nakabayashi, T., Tobise, K., Abe, S., Suzuki, S., Hayashi, I., Kawakami, Y., Matsuda, T., Tsuchiya, S., Takahashi, S., Tamura, T., and Saijo, N. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J. Clin. Oncol., 15: 304-309, 1997.
21. Cusack, J. C., Spitz, F. R., Nguyen, D., Zhang, W. W., Cristiano, R. J., and Roth, J. A. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther., 3: 245-249, 1996.
22. Jobin, C., Panja, A., Hellerbrand, C., Iimuro, Y., Didonato, J., Brenner, D. A., and Sartor, R. B. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial ceils. J. Immunol., 160: 410-418, 1998.
23. Haskill, S., Beg, A. A., Tompkins, S. M., Morris, J. S., Yurochko, A. D., Sampson-Johannes, A., Mondal, K., Ralph, P., and Baldwin, A. S., Jr. Characterization of an immediate-early gene induced in adherent monocytes that encodes I κB-like activity. Cell, 65: 1281-1289, 1991.
24. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
25. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
26. Cusack, J. C., Wang, C.-Y., Liu, R., and Baldwin, A. S. Chemosensitization of colorectal cancer cells by expression of the NF-κB super-represser IκBa. Surg. Forum, 48: 815-817, 1997.
27. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell, 87: 565-576, 1996.
28. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science (Washington DC), 274: 787-789, 1996.
29. Beg, A. A., and Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science (Washington DC), 274: 782-784, 1996.
30. Tartaglia, L. A., and Goeddel, D. V. Two TNF receptors. Immunol. Today, 13: 151-153, 1992.
31. Santana, P., Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E. H., Fuks, Z., and Kolesnick, R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell, 86: 189-199, 1996.
32. Hsu, H., Huang, J., Shu, H. B., Baichwal, V., and Goeddel, D. V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity, 4: 387-396, 1996.
33. Hsu, H., Xiong, J., and Goeddel, D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell, 81: 495-504, 1995.
34. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell, 82: 405-414, 1995.
35. Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and Green, D. R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell, 1: 543-551, 1998.
36. Kasibhatla, S., Genestier, L., and Green, D. R. Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor κB. J. Biol. Chem., 274: 987-992, 1999.
37. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997 [published erratum appears in CA Cancer J. Clin., 47: 68, 1997]. CA Cancer J. Clin., 47: 5-27, 1997.
38. Eisenberg, B., Decosse, J. J., Harford, F., and Michalek, J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer (Phila.), 49: 1131-1134, 1982.
39. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
40. Kerr, J. F., Winterford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy [published erratum appears in Cancer. 73: 3108, 1994]. Cancer (Phila.), 73: 2013-2026, 1994.
41. Steller, H. Mechanisms and genes of cellular suicide. Science (Washington DC), 267: 1445-1449, 1995.
42. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J. A., Hickish, T. S., Heikkila, R., Johannesen, T., Starkhammar, H., Topham, C. A., Ong, E., Herait, P., and Jaques, C. A Phase III multicenter randomized study of CPT-11 versus supportive care (SC) alone in patients (Pts) with 5-FU-resistant metastatic colorectal cancer (MCRC). Proc. Am. Assoc. Clin. Oncol., 17: 1, 1998.
43. Abigerges, D., Chabot, G. G., Armand, J. P., Herait, P., Gouyette, A., and Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
44. Nieves-Neira, W., and Pommier, Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer, 82: 396-404, 1999.
45. Goldwasser, F., Bae, I., Valenti, M., Torres, K., and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res., 55: 2116-2121, 1995.